.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Covington
Dow
Express Scripts
Chubb
McKinsey
Federal Trade Commission
Cipla
Daiichi Sankyo

Generated: September 24, 2017

DrugPatentWatch Database Preview

Schering Company Profile

« Back to Dashboard

What is the competitive landscape for SCHERING, and what generic alternatives to SCHERING drugs are available?

SCHERING has one hundred and two approved drugs.

There are nine US patents protecting SCHERING drugs on SCHERING drugs in the past three years.

There are eighty-three patent family members on SCHERING drugs in thirty-two countries.

Summary for Applicant: Schering

Patents:9
Tradenames:64
Ingredients:56
NDAs:102
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-004Dec 29, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
CHLOR-TRIMETON
chlorpheniramine maleate
SYRUP;ORAL006921-006Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
METICORTELONE
prednisolone acetate
INJECTABLE;INJECTION010255-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
DIPROLENE
betamethasone dipropionate
GEL, AUGMENTED;TOPICAL019408-002Nov 22, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
DIPROSONE
betamethasone dipropionate
CREAM;TOPICAL017536-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
PROVENTIL
albuterol
AEROSOL, METERED;INHALATION017559-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
METRETON
prednisolone sodium phosphate
SOLUTION/DROPS;OPHTHALMIC083834-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
CELESTONE
betamethasone
TABLET;ORAL012657-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 1998APRXYesYes► Subscribe► Subscribe► Subscribe
Schering
PROPRANOLOL HYDROCHLORIDE
propranolol hydrochloride
TABLET;ORAL070122-001Aug 6, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Schering

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering
NORMODYNE
labetalol hydrochloride
TABLET;ORAL018687-002Aug 1, 1984► Subscribe► Subscribe
Schering
LOTRIMIN
clotrimazole
LOTION;TOPICAL018813-001Feb 17, 1984► Subscribe► Subscribe
Schering
NORMODYNE
labetalol hydrochloride
TABLET;ORAL018687-004Aug 1, 1984► Subscribe► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 1998► Subscribe► Subscribe
Schering
PROVENTIL
albuterol sulfate
SOLUTION;INHALATION019243-001Jan 14, 1987► Subscribe► Subscribe
Schering
EULEXIN
flutamide
CAPSULE;ORAL018554-001Jan 27, 1989► Subscribe► Subscribe
Schering
NORMOZIDE
hydrochlorothiazide; labetalol hydrochloride
TABLET;ORAL019046-001Apr 6, 1987► Subscribe► Subscribe
Schering
LOTRIMIN
clotrimazole
LOTION;TOPICAL018813-001Feb 17, 1984► Subscribe► Subscribe
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-003Dec 29, 1994► Subscribe► Subscribe
Schering
VANCENASE
beclomethasone dipropionate
AEROSOL, METERED;NASAL018521-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SCHERING drugs

Drugname Dosage Strength Tradename Submissiondate
posaconazole
Injection18 mg/mL, 16.7 mL vials
NOXAFIL
11/24/2015
posaconazole
Delayed-release Tablets100 mg
NOXAFIL
6/16/2014
posaconazole
Oral Suspension40 mg/mL
NOXAFIL
2/28/2011
eptifibatide
Injection0.75 mg/mL, 100 mL vial
INTEGRILIN
6/5/2009
eptifibatide
Injection2 mg/mL, 100 mL vial
INTEGRILIN
12/18/2008
eptifibatide
Injection2 mg/mL, 10 mL vial
INTEGRILIN
9/30/2008

Non-Orange Book Patents for Schering

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,693,626 Tetrahydrofuran antifungals► Subscribe
5,714,490 Tetrahydrofuran antifungals► Subscribe
5,710,154 Tetrahydrofuran antifungals► Subscribe
5,703,236 Tetrahydrofuran antifungals► Subscribe
5,703,079 Tetrahydrofuran antifungals► Subscribe
6,713,481 Crystalline antifungal polymorph► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Schering Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)9638443► Subscribe
Brazil1100154► Subscribe
Canada2443089► Subscribe
Poland212985► Subscribe
Norway962616► Subscribe
Australia2006200354► Subscribe
Canada2179396► Subscribe
Germany69428125► Subscribe
Malaysia130217► Subscribe
China1499930► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Schering Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
323Luxembourg► SubscribePRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
C/GB08/005United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
90043Netherlands► SubscribePRODUCT NAME: EPTIFIBATIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: EU/1/99/109/001 - EU/1/99/109/002 19990701; FIRST REGISTRATION: CH 54050, 54054 19970227
0814Netherlands► SubscribePRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
216Luxembourg► Subscribe91216, EXPIRES: 20191220
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
2009 00017Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Cerilliant
Fish and Richardson
Accenture
Baxter
Mallinckrodt
Merck
Argus Health
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot